EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents

Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang, Abdullah Khan iD, David Bond, Yazeed Sawalha, John Reneau, Lapo Alinari, Robert Baiocchi, Beth Christian und 8 weitere

Cancer Medicine · 2023-04 · 12 (7) · 8228-8237

DOI: 10.1002/cam4.5631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 18.01.2023. Verfasst von Muhammad Salman Faisal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo‐HCT) at our center from 2001–2017.

Methods

The patients were divided into two distinct treatment cohorts: era1 (2001–2010), and era2 (2011–2017). The primary endpoint was overall survival (OS). Secondary endpoints included progression‐free survival (PFS), non‐relapse mortality (NRM), and cumulative incidence of acute and chronic graft versus host disease (GVHD).

Results

Among the 51 patients included in the study, 29 were in era1, and 22 were in era2. There was decreased use of myeloablative conditioning in era2 (18% vs. 31%) compared to era1 and 95% of patients in era2 previously received brentuximab Vedotin (BV). Haploidentical donors were seen exclusively in era2 (0% vs. 14%) and more patients received alternative donor transplants (7% vs. 32%) in era2. The 4‐year OS (34% vs. 83%, p < 0.001) and 4‐year PFS (28% vs. 62%, p = 0.001) were significantly inferior in era1 compared to era2. The incidence of 1‐year NRM was lower in era2 compared to era1 (5% vs. 34%, p = 0.06). The cumulative incidence of acute GVHD at day 100 was similar in both eras ( p = 0.50), but the incidence of chronic GVHD at 1 year was higher in era2 compared to era1 (55% vs. 21%, p = 0.03).

Conclusions

Despite the advent of novel therapies, allo‐HCT remains an important therapeutic option for patients with R/R HL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansBrentuximab VedotinNeoplasm Recurrence, LocalChronic DiseaseTransplantation ConditioningRetrospective Studies

Stichwörter der Autor:innen

Allo-HCTHodgkin lymphomaallogeneic hematopoietic cell transplantationrelapsed/refractorysurvival

Substanzen

Brentuximab Vedotin

Autor:innen und Institutionen

  • Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
  • Division of Hematology and Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Division of Hematology and Oncology, OhioHealth Bing Cancer Center, Columbus, Ohio, USA.

ORCID-Profile: Abdullah Khan, Narendranath Epperla

Zitieren

APA

Faisal, M. S., Hanel, W., Voorhees, T., Li, R., Huang, Y., Khan, A., Bond, D., Sawalha, Y., Reneau, J., Alinari, L., Baiocchi, R., Christian, B., Maddocks, K., Efebera, Y., Penza, S., Saad, A., Brammer, J., DeLima, M., Jaglowski, S., & Epperla, N. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine, 12(7), 8228-8237. https://doi.org/10.1002/cam4.5631

Vancouver

Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, et al. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 2023;12(7):8228-8237. doi:10.1002/cam4.5631

BibTeX
@article{Faisal2023,
  author = {Faisal, Muhammad Salman and Hanel, Walter and Voorhees, Timothy and Li, Rui and Huang, Ying and Khan, Abdullah and Bond, David and Sawalha, Yazeed and Reneau, John and Alinari, Lapo and Baiocchi, Robert and Christian, Beth and Maddocks, Kami and Efebera, Yvonne and Penza, Sam and Saad, Ayman and Brammer, Jonathan and DeLima, Marcos and Jaglowski, Samantha and Epperla, Narendranath},
  title = {Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {8228--8237},
  doi = {10.1002/cam4.5631}
}
Kostenlos starten →